More Adults Over 65 Are Taking GLP-1s—Here’s Why Doctors Urge Caution

Health
Original Story by Health
November 16, 2026
More Adults Over 65 Are Taking GLP-1s—Here’s Why Doctors Urge Caution

Rising use of GLP-1 medications among adults 65 and older is driven by expanded Medicare access, with a Bridge program offering $50 monthly copays through 2027, potentially benefiting millions but raising safety concerns for seniors. While many older patients experience meaningful weight loss and improved cardiometabolic markers, risks such as appetite loss, malnutrition, muscle and bone deterioration, and GI symptoms require careful management. Clinicians advocate pairing GLP-1 therapy with exercise, nutrition support, and gradual dosing, tailoring decisions to individual health status. The outlook hinges on balancing benefits with risks in the elderly, emphasizing ongoing medical supervision and lifestyle interventions. Decisions should prioritize health improvements and quality of life over mere weight metrics.

Dive Deeper:

  • From 2024 to 2025, the share of adults 65+ taking GLP-1s for weight management nearly doubled, rising from about 4.6% to 11.1%, with expectations of further increases due to Medicare’s Bridge program offering $50 monthly copays through December 2027.

  • GLP-1s were originally approved for diabetes and obesity but have expanded to cardiovascular and other age-related conditions; trials in older adults show meaningful weight loss and cardiometabolic benefits, yet risks such as appetite loss, dehydration, and malnutrition rise with age.

  • A 2026 preprint study of over 13,000 adults 65+ on tirzepatide found higher rates of appetite loss, dehydration, and malnutrition as weight loss increased, with those complications associated with increased hospitalization and ICU admissions, though causality was not established.

  • Clinicians interviewed emphasize co-prescribing exercise and a dietitian, and they adjust by lowering doses or switching to simpler GLP-1s when weight loss becomes excessive or GI symptoms occur, highlighting a focus on function and quality of life over scale metrics.

  • Patient experiences vary: some report substantial improvements in mobility and daily activity, while others struggle with GI symptoms or insufficient nutrition, leading to personalized dosing and long-term treatment decisions.

  • Starting guidance for seniors includes selecting a weaker initial option (e.g., semaglutide), slow dose escalation, ensuring adequate protein and strength training, and avoiding telehealth-only prescriptions without ongoing medical support.

  • Overall, the evidence remains encouraging but incomplete for older populations; experts urge individualized risk assessment and clinician involvement to optimize safety and functional outcomes rather than chasing weight-loss numbers.

Latest News

Related Stories